rethinkTHC Search
Menu
Study breakdown

Blocking cannabinoid receptors reversed memory problems caused by ecstasy withdrawal in mice

Animal StudyPreliminary evidence
The takeaway

A cannabinoid CB1 receptor antagonist (AM251) reversed recognition memory impairment during MDMA withdrawal in mice, linked to increased CB1 receptor protein in the hippocampus.

Read this if you are interested in how the endocannabinoid system relates to cognitive problems after ecstasy use.

CB1 knockout mice showed no memory impairment during MDMA withdrawal

What the researchers found

Mice received MDMA (ecstasy) daily for 7 days. On the 7th day of withdrawal, recognition memory was significantly impaired in a novel object recognition test.

The cannabinoid CB1 receptor antagonist AM251 blocked this memory impairment when given either before the test or alongside MDMA during the treatment period. CB1 receptor protein levels increased significantly in the hippocampus during MDMA withdrawal, but not in the prefrontal cortex or striatum.

Co-administration of AM251 with MDMA prevented the hippocampal CB1 receptor increase. Additionally, CB1 receptor knockout mice showed no recognition memory impairment during MDMA withdrawal, confirming the role of CB1 receptors in this effect.

Why it matters

The study identified the endocannabinoid system as a key mediator of memory impairment during MDMA withdrawal, potentially opening therapeutic targets for cognitive recovery in ecstasy users.

The numbers in context

MDMA dose: 10 mg/kg daily for 7 days. Memory tested at withdrawal day 7. CB1 protein increased significantly in hippocampus but not prefrontal cortex or striatum.

How the study worked

Controlled animal study in mice. MDMA (10 mg/kg i.p.) administered daily for 7 days. Novel object recognition test performed on withdrawal day 7. CB1 receptor protein measured by western blotting. Multiple experimental conditions tested: AM251 before testing, AM251 co-administered with MDMA, and CB1 knockout mice.

What this study cannot tell us

Mouse model using high daily MDMA doses that may not reflect human recreational use patterns. The novel object recognition test captures only one type of memory. Withdrawal period was limited to 7 days.

How to read the evidence

Well-controlled animal study with multiple experimental conditions and knockout confirmation, but limited to mouse models.

When this study was published

Published in 2010. Research on cross-drug interactions involving the endocannabinoid system has continued.

The bigger picture

This research connected ecstasy-related cognitive problems to the endocannabinoid system, adding to understanding of how different drug systems interact in the brain during withdrawal.

Questions still open

  • Would CB1 antagonists help ecstasy users recover cognitive function? Do similar endocannabinoid changes occur in the human hippocampus during MDMA withdrawal?

Common questions

What does this have to do with cannabis?
The study focused on cannabinoid CB1 receptors, which are the same receptors activated by THC in cannabis. MDMA withdrawal upregulated these receptors in the hippocampus, causing memory problems.
Could this help people who have used ecstasy?
The findings suggest CB1 receptor antagonists might help reverse cognitive impairment from MDMA use, but this has not been tested in humans.

Read the original research

A cannabinoid CB(1) receptor antagonist ameliorates impairment of recognition memory on withdrawal from MDMA (Ecstasy).

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 35(2), 515-20

Citation

Nawata, Yoko; Hiranita, Takato; Yamamoto, Tsuneyuki. (2010). A cannabinoid CB(1) receptor antagonist ameliorates impairment of recognition memory on withdrawal from MDMA (Ecstasy).. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 35(2), 515-20. https://doi.org/10.1038/npp.2009.158

Explore the wider topic